Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8994363 | Journal of Pharmaceutical Sciences | 2005 | 10 Pages |
Abstract
A smallâmolecule inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR), 3â[(3âtrifluoromethyl)phenyl]â5â[(4âcarboxyphenyl)methylene]â2âthioxoâ4âthiazolidinone (CFTRinhâ172), reduces enterotoxinâinduced intestinal fluid secretion in rodents. Here, we study CFTRinhâ172 pharmacology and antidiarrheal efficacy in rodents using 14Câlabeled CFTRinhâ172, liquid chromatography/mass spectrometry, and a closed intestinal loop model of fluid secretion. CFTRinhâ172 was cleared primarily by renal glomerular filtration without chemical modification. CFTRinhâ172 accumulated in liver within 5 min after intravenous infusion in mice, and was concentrated fivefold in bile over blood. At 30-240 min, CFTRinhâ172 was found mainly in liver, intestine, and kidney, with little detectable in the brain, heart, skeletal muscle, or lung. Pharmacokinetic analysis in rats following intravenous bolus infusion showed a distribution volume of 770 mL with redistribution and elimination halfâtimes of 0.14 h and 10.3 h, respectively. CFTRinhâ172 was stable in hepatic microsomes. Closedâloop studies in mice indicated that a single intraperitoneal injection of 20 μg CFTRinhâ172 inhibited fluid accumulation at 6 h after cholera toxin by >90% in duodenum and jejunum, â¼60% in ileum and <10% in colon. No toxicity was seen after highâdose CFTRinhâ172 administration (3 mg/kg/day in two daily doses) in mice over the first 6 weeks of life. The metabolic stability, enterohepatic recirculation, slow renal elimination, and intestinal accumulation of CFTRinhâ172 account for its efficacy as an antidiarrheal.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
N.D. Sonawane, Chatchai Muanprasat, R.a.y. Jr., Yuanlin Song, A.S. Verkman,